drugset / Trial / NCT00584740

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

NCT00584740

Phase 2 Terminated 59 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.

Timeline

Start
2008-08
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody 10 mg/kg Intravenous

Indications